간편하게 보는 뉴스는 유니콘뉴스
Galderma’s Relfydess™ (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe

· 등록일 Jul. 30, 2024 14:32

· 업데이트일 2024-07-31 00:00:06

ZUG, SWITZERLAND--(Business Wire / Korea Newswire)--Galderma today announced that it has completed its European decentralized procedure (DCP), resulting in a positive decision for Relfydess™ (RelabotulinumtoxinA - previously referred to as QM1114). Relfydess™ is indicated for the temporary improvement in the appearance of moderate-to-severe glabellar lines (frown lines) at maximum frown and lateral canthal lines (crow’s feet) seen at maximum smile, alone or in combination, in adult patients under 65 years, when the severity of these lines has an important psychological impact on the patient.[9] Following the successful completion of the DCP, national approvals in the 16 concerned countries are now under finalization. Relfydess™ also received a marketing authorization in Australia earlier this year.

Relfydess™ is developed and manufactured by Galderma. It is the first and only ready-to-use liquid neuromodulator created with PEARL™ Technology that is designed to preserve molecule integrity to deliver a highly active, innovative, complex-free molecule, with up to 39% of patients seeing effects from day one and up to 75% of patients maintaining improvements for six months for frown lines and crow’s feet.[3,4,7,8] It is optimized for simple volumetric dosing, without reconstitution, to increase ease of use and help ensure consistent dose/volume.[1,10]

“With Relfydess™, Galderma is introducing a highly differentiated and innovative neuromodulator, reinforcing our leadership and strong growth in this field, and our commitment to developing and delivering the broadest portfolio in Injectable Aesthetics. As per the decentralized European approach, our teams are now finalizing the approval procedures at the country level, so we’re ready to launch in multiple markets early next year.” FLEMMING ØRNSKOV, M.D., MPH, CHIEF EXECUTIVE OFFICER GALDERMA

This positive decision, and the previous Therapeutic Goods Administration approval in Australia, were based on results from the phase III READY (RElabotulinumtoxin Aesthetic Development StudY) clinical trial program, which enrolled more than 1,900 participants. Results showed:[3,4,7,8]

· Improvement in both frown lines and crow’s feet versus placebo:
- In READY-1 and READY-2, treatment with Relfydess™ demonstrated a 96.3% none-or-mild responder rate for frown lines and 87.2% for crow’s feet, after one month, vs 4.5% and 11.9% for placebo, respectively.

· Onset of action as soon as day one:
- In READY-1 and READY-2, 39% of patients reported improvements for frown lines and 34% reported improvements for crow’s feet from day one.

· Sustained results for six months:
- In READY-1 and READY-2, up to 75% of patients maintained improvements for six months.
- At month one, up to 96% achieved none-or-mild frown lines and crow’s feet, which was sustained for six months in almost a quarter of patients.

· Patient satisfaction was maintained for six months following treatment.

“With the growing need for new innovations in the neuromodulator space, I’m excited that, with Relfydess™, we have a new treatment that delivers both fast and sustained results in a simple and convenient formulation, so we can achieve the desired outcomes for our patients quickly, effectively, and without compromise.” DR. SACHIN SHRIDHARANI LEAD INVESTIGATOR OF READY-1 TRIAL PLASTIC SURGEON AND FOUNDER OF LUXURGERY

Regulatory applications for Relfydess™ for the treatment of frown lines and crow’s feet will continue to be submitted and assessed by additional authorities globally.

About Relfydess™ (RelabotulinumtoxinA)

Pioneered by Galderma, Relfydess™ is the first and only ready-to-use liquid neuromodulator created with PEARL™ Technology that is designed to preserve molecule integrity.[1,2] PEARL™ Technology is designed to deliver a highly active, innovative, complex-free molecule, with up to 39% of patients seeing effects from day one and up to 75% of patients maintaining improvements for six months.[1-4,7,8] Relfydess™ is optimized for simple volumetric dosing, without reconstitution, to increase ease-of-use and help ensure consistent dose/volume every time.[1,10] It was entirely developed and manufactured by Galderma to expand its neuromodulator portfolio as part of the broadest Injectable Aesthetics portfolio on the market.

About the READY clinical trial program

The READY (RElabotulinumtoxin Aesthetic Development StudY) phase III clinical program is composed of four phase III clinical trials which enrolled more than 1,900 participants.3-6 The READY trials investigated the safety, efficacy, rapidity of onset and/or durability of Relfydess™ for six months on:

· Frown lines (READY-1).[3]
· Crow’s feet (READY-2).[4]
· Frown lines and crow’s feet when treated alone or simultaneously (READY-3).[5]
· Frown lines and crow’s feet when treated alone or simultaneously with up to four repeated injections over 52 weeks (READY-4).[6]

About Galderma

Galderma (SIX: GALD) is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ - the skin - meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References:

[1] Sundberg AL and Stahl U. Relabotulinum toxin - a novel, high purity BoNT-A1 in liquid formulation. Presented at: TOXINS 2021; Jan 16-17, 2021; virtual meeting
[2] Do M, et al. Purification process of a complex-free highly purified botulinum neurotoxin type A1 (BoNT-A1) - relabotulinumtoxinA. Presented at: TOXINS 2022; July 27-30, 2022; New Orleans, LA
[3] Galderma. Data on file. Clinical Study Report for Protocol 43QM1602: READY-1. Galderma Laboratories; 2021
[4] Galderma. Data on file. Clinical Study Report for Protocol 43QM1901: READY-2. Galderma Laboratories; 2021
[5] Galderma. Data on file. Clinical Study Report for Protocol 43QM1902: READY-3. Galderma Laboratories; 2021
[6] Galderma. Data on file. Clinical Study Report for Protocol 43AM1903: READY-4. Galderma Laboratories; 2021
[7] Shridharani SM, et al. Efficacy and Safety of RelabotulinumtoxinA, a New Ready-to-Use Liquid Formulation Botulinum Toxin: Results From the READY-1 Double-Blind, Randomized, Placebo-Controlled Phase 3 Trial in Glabellar Lines. Aesthetic Surgery Journal. 2024; sjae131
[8] Ablon G, et al. Treatment of Lateral Canthal Lines with RelabotulinumtoxinA, an Investigational Liquid Botulinum Toxin: Clinical Efficacy and Safety Results from the READY-2 Phase III Trial. Abstract presented at TOXINS 2024; Jan 17-20, 2024, Berlin
[9] Relfydess® EU Summary of Product Characteristics
[10] Persson C, et al. Patient and Investigator Treatment Experience with Ready-to-Use AbobotulinumtoxinA Solution Versus Powder BotulinumtoxinA for Treatment of Glabellar Lines. Abstract presented at TOXINS 2024; Jan 17-20, 2024, Berlin

View source version on businesswire.com: https://www.businesswire.com/news/home/20240729848736/en/

Website: http://www.galderma.com Contact Galderma
Christian Marcoux, M.Sc.
Chief Communications Officer
+41 76 315 26 50
[email protected]

Sébastien Cros
Corporate Communications Director
+41 79 529 59 85
[email protected]

Emil Ivanov
Head of Strategy, Investor Relations, and ESG
+41 21 642 78 12
[email protected]

Jessica Cohen
Investor Relations and Strategy Director
+41 21 642 76 43
[email protected]
This news is a press release provided by Galderma. Korea Newswire follows these editorial guidelines. Galderma News ReleasesSubscribeRSS Galderma Delivers Record Net Sales of 2.2 Billion USD and 10.8% Year-on-Year Growth at Constant Currency for the First Half of 2024 Galderma Group AG, the pure-play dermatology category leader, today announced its financial results for the first half of 2024. · Record net sales of 2.2 billion USD in the first half of 2024, with net sales growth of 10.8% on a constant currency basis[1], predominantly driven by volume... 7월 25일 17:25 PHASE III ARCADIA 1 and 2 Trial Primary Results Published in The Lancet: Galderma’s Nemolizumab Improves Key Aspects of Atopic Dermatitis - Itch, Skin Lesions and Sleep Disturbance Galderma today announced that full results from the phase III ARCADIA 1 and 2 clinical trials in atopic dermatitis were published in The Lancet .[1]The trials evaluated the efficacy and safety of nemolizumab in combination with background topical corticosteroids (TCS), with or without t... 7월 25일 15:31 ... More  More News Health Clinical Trials Pharmaceutical R&D Overseas Galderma All News Releases 
인기 기사12.23 18시 기준
서울--(뉴스와이어)--GS리테일이 운영하는 GS샵이 여름 시즌 유통업계 공식이 된 ‘역(逆)시즌 마케팅’을 지난해보다 한 달 앞당겨 실시한다. GS샵 스튜디오에서 역시즌 상품을 방송하고 있다 ...
서울--(뉴스와이어)--포웍스컴퍼니(도서출판 책모종)는 ‘어린 암 환자를 위한 머리카락 나눔(어머나)’ 운동본부에 책을 기부했다고 13일 밝혔다. 어머나 운동본부는 항암치료 과정에서 머리카락이 빠지면서 생기는 소아암 환자들을 위해 머리카락을 기부받아 만든 맞춤형 가발을 무상으로 제공하고 있다. ...
MUMBAI, INDIA--(Business Wire / Korea Newswire)--Quectel Wireless Solutions, a global IoT solutions provider, today announces a collaboration with Syrma SGS Technology Ltd, a leading electronic manufacturing services provider, to facilitate the manufacturing of modules...
서울--(뉴스와이어)--도서출판 문학공원은 강원도 영월군 무릉도원면 남성의용소방대장으로 봉사하고 있는 이재업 시인이 두 번째 시집 ‘거꾸로 자라는 나무’를 출간했다고 밝혔다. 이재업 두 번째 시집 ‘거꾸로 자라는 나무’...
서울--(뉴스와이어)--삼성물산 건설부문(이하 삼성물산)이 신재생 에너지만을 활용해 그린수소를 생산하는 시설 구축에 나선다. 그린수소는 오로지 신재생 에너지만을 활용해 생산되는 수소로, 그린수소 생산시설을 건설하는 것은 국내 최초이다. 김천시 소재 그린수소 생산기지 구축 조감도 삼성물산은 경상북도 김천시에 오프그리드(Off-grid)[1] 태양광발전을...
CAMBRIDGE, MASS.--(Business Wire / Korea Newswire)--ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Amit D. Munshi, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare...
API
fg
유니콘뉴스는 보도자료 배포 서비스입니다.
여기에 뉴스를 등록하면 언론이 보도하고 널리 배포됩니다.